Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug-Sep:185:106477.
doi: 10.1016/j.rmed.2021.106477. Epub 2021 May 26.

Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure

Marianna Damiani  1 , Lucia Gandini  1 , Francesco Landi  2 , Gianmaria Borleri  2 , Fabrizio Fabretti  3 , Giuseppe Gritti  4 , Ivano Riva  5
Affiliations

Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure

Marianna Damiani et al. Respir Med. 2021 Aug-Sep.
No abstract available

Keywords: ARDS; COVID-19; CytoSorb; Cytokine storm; Extracorporeal treatment; Inflammatory response; Mechanical Ventilation.

PubMed Disclaimer

Conflict of interest statement

GG reports non-financial support from Gilead Kite, Roche, Takeda and Janssen, and personal fees from Gilead Kite, Autolus, Roche, IQvia, Takeda, Amgen and Italfarmaco, outside the submitted work. IR reports travel support from Aferetica. All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
(A–F) Individual level (dots), median level (bars) and interquartile range of serum cytokines before (enrolment) and after (post, after 24 hours and after 7 days) treatment with CytoSorb®. Statistical significance is referred to baseline level, comparison between the timepoints“enrolment” and “after 7 days” was done only for the 7 patients with available samples. (G–H) Daily median serum level and interquartile ranges of CRP and PaO 2/FiO 2 ratio for the first 15 days after enrolment (Day 0–14). Dotted rectangle indicates treatment period. A statistical significance difference from pre-treatment values (Day 0) is present from Day 3 to Day 14 for both parameters. Legend: IL: interleukin; TNF: tumour necrosis factor; CRP: C-reactive protein.
figs1
figs1
See this image and copyright information in PMC

References

    1. Guan W., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. - PMC - PubMed
    1. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 2017;39:529–539. - PMC - PubMed
    1. Brunetta E., et al. Macropahge expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat. Immunol. 2020 doi: 10.1101/2020.06.26.20139923. - DOI - PubMed
    1. Gritti G., et al. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. Leukemia. 2021 doi: 10.1038/s41375-021-01299-x. - DOI - PMC - PubMed
    1. Rambaldi A., et al. Endothelial injury and thrombotic microangiopathy in COVID-19: treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology. 2020:152001. doi: 10.1016/j.imbio.2020.152001. - DOI - PMC - PubMed

Publication types

LinkOut - more resources